The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

被引:42
|
作者
Weiden, Peter J. [1 ]
Roma, Rebecca S. [2 ]
Velligan, Dawn I. [3 ]
Alphs, Larry [4 ]
DiChiara, Matthew [5 ]
Davidson, Brad [5 ]
机构
[1] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA
[3] Mercy Behav Hlth Pittsburgh, Community Treatment Team, Pittsburgh, PA USA
[4] Janssen Sci Affairs, Therapeut Area Lead Psychiat, Titusville, NJ USA
[5] Ogilvy CommonHlth Behav Insights, Parsippany, NJ USA
关键词
Antipsychotics; Delivery of Care; Schizophrenia; SHARED DECISION-MAKING; IN-OFFICE; PERSPECTIVES; ADHERENCE; DEPOT; COMMUNICATION; PERCEPTIONS; STRATEGIES; ATTITUDES; PROVIDER;
D O I
10.4088/JCP.13m08946
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To characterize patterns of communication in the offer of long-acting injectable (LAI) antipsychotic medication made by psychiatrists to patients with schizophrenia by (1) examining the style and content of their interaction and (2) determining how these may have driven the ultimate response to recommendations for LAI therapy. Method: This was an observational study conducted at 10 community mental health centers in 3 waves from July 2010 to May 2011. The final dataset for discourse analysis was 33 recorded conversations in which a psychiatrist offered an injectable antipsychotic to a patient with schizophrenia. These visits were transcribed and analyzed by a team of linguists and social scientists. Results: Our primary finding is that, based on analyses of their language during the interview, psychiatrists presented LAI therapy in a negative light. Supporting this, 11 of 33 recommendations (33%) were accepted during the discussion, whereas in the postvisit interview, 27 of 28 patients (96%) who seemed to decline the initial recommendation said they actually would be willing to try LAI treatment. Conclusions: These data support a preliminary hypothesis that the relatively low use of injectable antipsychotic therapies in the United States relative to other parts of the world is not fully attributable to patient rejection of the injectable modality. Rather, psychiatrists' ambivalence regarding the value of LAIs may play a significant role in the perceived difficulty with patient acceptance of this recommendation. (c) Copyright 2015 Physicians Postgraduate Press, Inc.
引用
收藏
页码:684 / 690
页数:7
相关论文
共 50 条
  • [1] Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients with Schizophrenia
    Morton, N. Kirk
    Zubek, Donna
    JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2013, 51 (03) : 13 - 18
  • [2] Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia
    Eun Ji Park
    Sarmila Amatya
    Myung Sun Kim
    Jong Hoon Park
    Eunyoung Seol
    Heeyong Lee
    Young-Hee Shin
    Dong Hee Na
    Archives of Pharmacal Research, 2013, 36 : 651 - 659
  • [3] Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia
    Park, Eun Ji
    Amatya, Sarmila
    Kim, Myung Sun
    Park, Jong Hoon
    Seol, Eunyoung
    Lee, Heeyong
    Shin, Young-Hee
    Na, Dong Hee
    ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (06) : 651 - 659
  • [4] An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia
    Dursun, S
    JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (05) : 3 - 4
  • [5] Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia
    Carpenter, William T., Jr.
    Buchanan, Robert W.
    JAMA PSYCHIATRY, 2015, 72 (08) : 745 - 746
  • [6] Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    EARLY INTERVENTION IN PSYCHIATRY, 2020, 14 (04) : 428 - 438
  • [7] Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy
    Alphs, Larry
    Nasrallah, Henry A.
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Gopal, Srihari
    Hough, David
    Turkoz, Ibrahim
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (04) : 202 - 209
  • [8] Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
    Kane, John M.
    McEvoy, Joseph P.
    Correll, Christoph U.
    Llorca, Pierre-Michel
    CNS DRUGS, 2021, 35 (11) : 1189 - 1205
  • [9] Long-Acting Injectable Antipsychotic Medications in Patients With Comorbid Schizophrenia and Substance Use Disorders
    Green, Alan I.
    JOURNAL OF DUAL DIAGNOSIS, 2012, 8 (01) : 62 - 63
  • [10] Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
    Bhatta, Madhav P.
    Bista, Saroj
    El Khoury, Antoine C.
    Hutzell, Eric G.
    Tandon, Neeta
    Smith, Douglas
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (01): : 63 - 70